Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

14.03USD
1:17pm EDT
Change (% chg)

$0.61 (+4.55%)
Prev Close
$13.42
Open
$13.70
Day's High
$14.30
Day's Low
$13.67
Volume
151,199
Avg. Vol
215,464
52-wk High
$19.91
52-wk Low
$8.70

Select another date:

Wed, May 24 2017

BRIEF-Insys Therapeutics announces FDA final product label for Syndros

* Insys Therapeutics Inc says syndros is approved for use in treating anorexia associated with weight loss in patients with acquired immune deficiency syndrome

BRIEF-Insys Therapeutics announces chief financial officer transition

* Insys Therapeutics announces chief financial officer transition

Insys in talks with U.S. to resolve probe of opioid spray

BOSTON Insys Therapeutics Inc's chief executive said on Tuesday it was working to resolve a U.S. Justice Department probe, after prosecutors accused several former executives of leading a scheme to bribe doctors to prescribe a fentanyl-based pain medication.

Insys in talks with U.S. to resolve probe of opioid spray

BOSTON, May 9 Insys Therapeutics Inc's chief executive said on Tuesday it was working to resolve a U.S. Justice Department probe, after prosecutors accused several former executives of leading a scheme to bribe doctors to prescribe a fentanyl-based pain medication.

BRIEF-Insys Therapeutics reports Q1 loss per share $0.09

* Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S

BRIEF-Insys therapeutics accepts resignation of Santosh Vetticaden, interim CEO

* On April 11, 2017, Insys Therapeutics accepted resignation of Santosh Vetticaden, interim chief executive officer Source text for Eikon: Further company coverage:

Insys' revenue plunges as Subsys prescriptions fall

Insys Therapeutics Inc on Monday reported a 41.6 percent decline in quarterly revenue, hurt by a fall in demand for Subsys, an opioid spray approved for managing pain in cancer patients.

UPDATE 1-Insys' revenue plunges as Subsys prescriptions fall

April 3 Insys Therapeutics Inc on Monday reported a 41.6 percent decline in quarterly revenue, hurt by a fall in demand for Subsys, an opioid spray approved for managing pain in cancer patients.

Insys Therapeutics' revenue falls 41.6 pct

April 3 Insys Therapeutics Inc on Monday reported a 41.6 percent decline in quarterly revenue, hurt by a fall in demand for its pain drug, Subsys.

Insys to restate some financial statements

Insys Therapeutics Inc said on Friday that it will restate some financial statements due to the identification of certain errors.

Select another date:

More From Around the Web